VEGFA and hepatocellular carcinoma: The main driver of the overall benefit associated with ICIs found in this meta-analysis was the data obtained from the IMbrave150 study, which evaluated the combination of anti–PD-L1 plus anti–vascular endothelial growth factor (VEGF) therapy.15,16 ICIs as monotherapy have demonstrated limited efficacy in the systemic treatment of HCC.